Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13555: Variant p.Arg292Pro

Calcium/calmodulin-dependent protein kinase type II subunit gamma
Gene: CAMK2G
Feedback?
Variant information Variant position: help 292 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Proline (P) at position 292 (R292P, p.Arg292Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and hydrophobic (P) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MRD59; gain-of-function variant affecting regulation of neurite formation and arborization; results in constitutive autophosphorylation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 292 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 558 The length of the canonical sequence.
Location on the sequence: help VCQRSTVASMMHRQETVECL R KFNARRKLKGAILTTMLVSR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VCQRSTVASMMHRQETVECLRKFNARRKLKGAILTTMLVSR

Mouse                         VCQRSTVASMMHRQETVECLRKFNARRKLKGAILTTMLVSR

Rat                           VCQRSTVASMMHRQETVECLRKFNARRKLKGAILTTMLVSR
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 558 Calcium/calmodulin-dependent protein kinase type II subunit gamma
Region 283 – 292 Autoinhibitory domain
Modified residue 287 – 287 Phosphothreonine; by autocatalysis
Modified residue 306 – 306 Phosphothreonine; by autocatalysis
Modified residue 307 – 307 Phosphothreonine; by autocatalysis
Modified residue 311 – 311 Phosphoserine
Helix 285 – 301



Literature citations
Diagnostic exome sequencing in persons with severe intellectual disability.
de Ligt J.; Willemsen M.H.; van Bon B.W.; Kleefstra T.; Yntema H.G.; Kroes T.; Vulto-van Silfhout A.T.; Koolen D.A.; de Vries P.; Gilissen C.; del Rosario M.; Hoischen A.; Scheffer H.; de Vries B.B.; Brunner H.G.; Veltman J.A.; Vissers L.E.;
N. Engl. J. Med. 367:1921-1929(2012)
Cited for: VARIANT MRD59 PRO-292; INVOLVEMENT IN MRD59; The intellectual disability-associated CAMK2G p.Arg292Pro mutation acts as a pathogenic gain-of-function.
Proietti Onori M.; Koopal B.; Everman D.B.; Worthington J.D.; Jones J.R.; Ploeg M.A.; Mientjes E.; van Bon B.W.; Kleefstra T.; Schulman H.; Kushner S.A.; Kuery S.; Elgersma Y.; van Woerden G.M.;
Hum. Mutat. 39:2008-2024(2018)
Cited for: VARIANT MRD59 PRO-292; INVOLVEMENT IN MRD59; FUNCTION; CHARACTERIZATION OF VARIANT MRD59 PRO-292;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.